Stempeutics receives Rs.3.5 cr DBT fund for phase II trial of IMP for ... pharmabiz.com However, potential benefits are hampered by many drawbacks such as relative shortage of donors, operative risk, post transplant rejection, recidivism of the pre-existing liver disease, high costs and several complications. More advanced treatment is ... |
